A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Cannot have received: radiation therapy

Exception: must have measurable disease outside of the radiation field

Prior radiation or surgical resection of their lymphoma without additional sites of measurable disease outside of the radiation field

Cannot have received: radiation therapy

Exception: must be >2 weeks prior to first dose

subjects who have received prior radiation or surgical resection of their lymphoma ≤2 weeks prior to the first dose of study drug

Cannot have received: systemic cancer treatments

Exception: must be >4 weeks before enrollment or >5 half-lives since completion of previous investigational therapy, whichever is shorter

Systemic cancer treatments, monoclonal antibody-directed therapies, other investigational agents within 4 weeks before enrollment, or <5 half-lives since completion of previous investigational therapy, whichever is shorter.